
    
      Two arms, phase 3 study of neoadjuvant S1, oxaliplatin, and docetaxel (SLOT) versus S1,
      oxaliplatin(SOX) in patients with locally advanced, resectable gastric/esophagogastric
      junction (EGJ) cancer. 380 Patients will be enrolled in this trial. The primary objective of
      this study is to determine the 5-year survival of the two arms.
    
  